

Call for Incentive Research Collaboration 2025 Laureate

Project AppMedDD

Actionable prescribing protocols for medication risk
Associated with delirium in dementia

AURORA



Co-funded by
the European Union



PROJECT IDENTIFICATION

Project title:

Actionable prescribing protocols for medication risk associated with delirium in dementia.

Project acronym: AppMedDD

COORDINATOR



Principal researcher:

Univ.-Prof. Dr. Anita Weidmann

University:

Universität Innsbruck
Faculty of Chemistry and Pharmacy

Email: anita.weidmann@uibk.ac.at

PARTNERS

Principal researcher:

Assist. -Prof. Dr. Freyja Jónsdóttir

University:

University of Iceland (UI)
School of Health Sciences

Email: freyjaj@hi.is

Principal researcher:

Dr. rer. medic. Janine Biermann-Stallwitz, M.A.

University:

University of Duisburg-Essen
Faculty of Business Administration and Economics / Institute for Health Care
Management and Research

Email: Janine.Biermann@medman.uni-due.de

Principal researcher:

Prof. Dr. Carmel Hughes

University:

Queen's University Belfast
School of Pharmacy

Email: c.hughes@qub.ac.uk

Principal researcher:

Dr. Ivana Tadić

University:

Universität Innsbruck
Faculty of Chemistry and Pharmacy

Email: Ivana.Tadic@uibk.ac.at

Principal researcher:

Med.Dr. Aðalsteinn Guðmundsson

University:


Landspítali University Hospital
Geriatric division

Email: adalstg@landspitali.is

OBJECTIVE

This study aims to collate comprehensive information on pharmacological risk associated with the causation, treatment and prevention of delirium in dementia patients and determine its relevance in clinical prescribing practice.

ILLUSTRATION OF THE PROJECT



SOCIAL IMPACTS AND TARGETED SDG

Dementia affects 55 million people worldwide, costing healthcare systems approximately \$1.3 trillion, with projections reaching 153 million affected patients by 2050 due to population ageing. Delirium superimposed on dementia affects up to 49% of hospitalised adults over 65 years, carrying a cumulative 12-month mortality rate of 57%. Despite medication being identified as both a predisposing and precipitating factor for delirium, no prescribing protocols currently exist to guide clinical practice.

AppMedDD addresses this unmet need by:

- (1) collating pharmacological risk stratification tables based on evidence from four systematic reviews and two large-scale real-world database analyses; and

(2) developing key actionable prescribing guidance statements through focus group studies with an international expert panel of delirium and dementia clinicians.

Incorrect therapeutic decisions or failure to identify delirium in a timely manner result in significant additional healthcare costs and high patient mortality. The published results will be used to pursue larger funding opportunities for developing internationally applicable consensus prescribing guidelines and real-world feasibility testing, maximising translational impact.

This project aligns with UN SDG 3 (*Ensure healthy lives and promote well-being for all at all ages*) and the WHO Global Patient Safety Action Plan 2021–2030, demonstrating a commitment to reducing harm from non-communicable diseases and medication-related harm by 2030.

AURORA ADDED VALUE

Aurora facilitates access to a diverse pool of expertise needed for the development of clear actionable prescribing practice protocols for medication risk associated with delirium in dementia patients. It allows the research team to tap into an existing research infrastructure which will facilitate collaboration on several related research projects, research outputs and in-depth knowledge exchange. It allows the creation of training opportunities for early career researchers through PhD supervision, ERASMUS+ mobility and planned international summer schools.